GE HealthCare has launched CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relevant for disease progression from multiple data sources, and driving evidence-based clinical decision support directed by up-to-date AFib guidelines. The new technology was showcased at the European Society of Cardiology Congress 2023, in Amsterdam, Netherlands, in August.

Cardiovascular diseases are the leading cause of death globally, with more than 60% of these deaths being preventable and premature. Within the umbrella of cardiovascular disease, AFib is the most common arrhythmia diagnosed in clinical practice, affecting millions of people worldwide. Additionally, AFib is often misdiagnosed or not treated appropriately, with up to 30 percent of cases missed in routine clinical practice. It is critical that progress is made in driving precision care for the management of patients suffering from AFib as people living with the condition are five times more likely to experience a stroke and AFib is a common cause of hospitalization.

“Existing diagnosis and treatment care models for AFib have been shown to be complex, time consuming and disconnected with disparate guidelines and poor guideline adherence,” said Eigil Samset, PhD, general manager, Cardiology Solutions, GE HealthCare. “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool to tell the story of the heart, including previous diagnoses, prescribed medications, interventions, and comorbidities.”

CardioVisio for AFib assists the clinician in visualizing longitudinal data relevant for disease progression from multiple data sources, saving time and aiding clinical decision making by offering guideline-directed therapy recommendations. Each automated step includes explainability and traceability, allowing the healthcare provider to audit and edit the process and output with the goal of better meeting the unique needs of each AFib patient.

CardioVisio for Atrial Fibrillation is now commercially available in the U.S. The company plans to expand availability in other regions in the coming months incorporating additional regional guidelines.

For more information, visit: https://bit.ly/3tc8MCl 
Digital issue: Please click here for more information